Build, Buy, or Bond?
David H. Crean
Managing Partner
Cardiff Advisory
(858) 461-9490
Navigating the Growth Agenda for 2026
The fundamental question facing corporate executives—how to best allocate capital to achieve growth—remains as critical as ever. As we move deeper and towards to end of 2025, deal intentions are proving robust, building on the measured rebound that began in the previous year. Companies, particularly in the Life Sciences sector, continue to grapple with pipeline gaps and the urgent need to acquire competitive advantage in an environment defined by rapid technological change, regulatory shifts, and geopolitical volatility.
The corporate growth agenda is no longer a simple “Buy versus Build” decision; the third option, Bond, has solidified its place as an equally powerful, non-dilutive engine of growth.
Deep Dive on the Strategic Framework
The “Build, Buy, or Bond” framework outlines the three core methods for achieving strategic corporate growth and filling capability gaps. In 2025, the strategic rationale for each option has been amplified by the competitive landscape.
Build (Organic Growth)
Definition: Build, or organic growth, refers to achieving objectives internally through the development of existing resources, research and development (R&D), and capital investment within the company’s current structure.
| Pros | Cons |
|---|---|
| Full Control over development, culture, and intellectual property (IP). | Slowest path to market, increasing risk of being leapfrogged by competitors. |
| Lower Cost base upfront, avoiding high M&A premiums. | High Risk of R&D failure, with costs sunk into unsuccessful programs. |
| Culture Preservation, avoiding integration challenges. | Resource Constraints, requiring extensive internal talent and infrastructure. |
Build in 2025:
- For many industries, particularly in Life Sciences, the pace of innovation (e.g., in modalities like gene therapy or AI-driven drug discovery) makes Build a challenging primary strategy.
- However, strategic “Build” is crucial for integrating new technologies. Companies are investing heavily in-house to develop Generative AI and advanced data analytics capabilities that underpin all future innovation efforts.
Buy (Mergers & Acquisitions)
Definition: Buy involves acquiring external assets, technologies, pipelines, or entire companies through a merger or acquisition (M&A) to immediately gain market share or new capabilities.
| Pros | Cons |
|---|---|
| Speed—the fastest way to secure a competitive advantage or fill a product pipeline. | High Valuation Risk, especially for sought-after assets (e.g., AI companies). |
| Scale and immediate access to new markets or customer bases. | Integration Challenges, including cultural clashes and failure to realize promised synergies. |
| De-risked Assets compared to early-stage R&D. | Regulatory Scrutiny, especially for large or mega-deals, though the 2025 environment is seen as more favorable. |
Buy in 2025:
- M&A is experiencing a major rebound, driven by over $3 trillion in uncommitted capital and financial sponsors under pressure to monetize assets.
- We are seeing a resurgence of mega-deals ($10B+) as CEOs gain confidence, often with a focus on bolstering capabilities in AI.
- For Big Pharma, bolt-on acquisitions (smaller, strategic deals) remain the preferred way to quickly secure innovative pipelines and intellectual property.
Bond (Partnerships & Alliances)
Definition: Bond refers to forming a cooperative arrangement, such as a joint venture, licensing agreement, or strategic alliance, to share risk, resources, and reward without a full change of ownership.
| Pros | Cons |
|---|---|
| Shared Risk for expensive, long-duration R&D programs (critical in Life Sciences). | Shared Control and potential for misalignment of strategic goals and priorities. |
| Non-Dilutive Financing for pre-revenue companies, which is highly attractive when capital markets are volatile. | Complexity in negotiating and managing multi-faceted contractual relationships |
| Access to New Geographies or specialized technologies (e.g., Chinese R&D partners). | Limited Upside compared to an acquisition, as profits are split. |
Bond in 2025:
- Bonding remains the “life blood” for Life Sciences firms, especially for early-stage innovation.
- The trend is toward highly-structured risk-sharing deals through significant milestone and royalty payments, particularly in licensing agreements.
- Geopolitical uncertainty is driving a rise in cross-border alliances as companies seek to diversify geographically and build resilient supply chains.
What We’re Seeing in 2025: A Landscape of Strategic Adaptation
The decisions around “Build, Buy, or Bond” are being made against a backdrop of a global economy marked by cautious optimism, strategic sector-specific tailwinds, and disruptive technology.
Macro and Capital Markets
The macroeconomic environment has shifted considerably over the past 10 years. In 2025, key factors influencing capital allocation include:
- Monetary Policy Shift: Expected interest rate cuts by central banks are making capital more accessible, which is anticipated to facilitate larger deals and increase the attractiveness of the Buy option.
- Bond Market Appeal: Higher starting yields and expected rate cuts have made high-quality bonds a compelling source of stable income and portfolio diversification, offering a competitive alternative to cash for corporate treasuries.
- Policy & Geopolitical Uncertainty: Despite an anticipated favorable regulatory environment for M&A under a new U.S. presidential administration, uncertainties regarding tariffs and geopolitical developments are prompting companies to seek geographical diversification through both Buy (cross-border M&A) and Bond (strategic alliances).
Sector Focus: The Life Sciences Deal Boom
The Life Sciences sector is a prime example of the “Buy and Bond” strategies dominating the growth agenda.
- Pipeline Urgency: Big Pharma faces massive growth gaps and has significant M&A “firepower” to address patent cliffs. This need drives M&A toward both established assets and earlier-stage innovation.
- The AI Imperative: The race for Artificial Intelligence (AI) leadership is a major deal driver, with companies inking both M&A and licensing deals to secure AI-driven drug discovery platforms and applications.
- Dual-Track Exits: As capital markets strengthen, early-stage Life Sciences companies are increasingly using a dual-track process—simultaneously preparing for an IPO and an M&A exit—to maximize optionality and pressure bidders to offer better terms.
Conclusion
In 2025, corporate strategy is defined by agility and flexibility. The Build, Buy, or Bond decision is rarely singular; it is a dynamic portfolio approach. Companies are:
- Building core competencies in AI and data.
- Buying growth and scale through strategic bolt-on deals and selective mega-acquisitions.
- Bonding to share risk, access specialized technologies, and secure non-dilutive capital, especially in the earliest stages of innovation.
For forward-looking companies, the successful execution of this blended strategy is the key to navigating a volatile global environment and securing sustainable long-term growth.
Disclosure
David H. Crean, Ph.D., is a Managing Partner for Cardiff Advisory LLC, an M&A investment banking strategic advisory firm focused on the Life Sciences and Healthcare sectors. This article is provided for informational purposes only and does not constitute an offer, invitation, or recommendation to buy, sell, subscribe for or issue any securities.
The principals of Cardiff Advisory LLC are registered representatives of BA Securities, LLC Member FINRA SIPC, located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 400 W. Conshohocken, PA 19428. Cardiff Advisory LLC and BA Securities, LLC are unaffiliated entities. All investment banking services and securities are offered through BA Securities, LLC, Member FINRA SIPC.